Lung Cancer | Specialty

Rationale for I/O therapy in Extensive-Stage Small Cell Lung Cancer

December 11th 2020

Aggressive Nature of Extensive-Stage Small Cell Lung Cancer

December 11th 2020

Differentiating Small Cell Lung Cancer and Non-Small Cell Lung Cancer

December 11th 2020

Background of Small Cell Lung Cancer

December 11th 2020

Dr. Ferrarotto on the Mechanism of Action of Trilaciclib in ES-SCLC

December 10th 2020

Renata Ferrarotto, MD, discusses the mechanism of action of trilaciclib in extensive-stage small cell lung cancer.

Trilaciclib Prior to Myelosuppressive Chemo Reduces Need for Supportive Care in Small Cell Lung Cancer

December 9th 2020

Renata Ferrarotto, MD, discusses trilaciclib’s unique mechanism of action in small cell lung cancer and the data that led to its FDA designation.

FDA Grants Breakthrough Therapy Designation to Sotorasib for KRAS G12C–Mutant Advanced or Metastatic NSCLC

December 8th 2020

December 8, 2020 - The FDA has granted a breakthrough therapy designation to sotorasib for use as a potential treatment in patients with KRAS G12C–mutated locally advanced or metastatic non–small cell lung cancer.

Dr. Mok on the Importance of Global Collaboration to Improve Cancer Care

December 3rd 2020

Tony S. K. Mok, MD, BMSc, FRCPC, FASCO, discusses the importance of improving cancer research through collaboration as a Giant of Cancer Care®.

Lurbinectedin/Doxorubicin Combo Misses OS End Point in Phase 3 SCLC Trial

December 3rd 2020

December 3, 2020 - Lurbinectedin plus doxorubicin failed to significantly improve overall survival versus physician’s choice of topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small cell lung cancer who progressed after 1 previous platinum-containing line of treatment, missing the primary end point of the phase 3 ATLANTIS trial.

FDA Approval Sought for Amivantamab for Metastatic EGFR Exon 20–Positive NSCLC

December 3rd 2020

December 3, 2020 — A biologics license application has been submitted to the FDA for the EGFR-MET bispecific antibody amivantamab for the treatment of patients with metastatic non–small cell lung cancer with EGFR exon 20 insertion mutations who have progressed on or following a platinum-based chemotherapy.

2020 Ushers in Newfound Adjustments, Applications in Lung Cancer

December 2nd 2020

Mark G. Kris, MD, discusses the strengths of this year’s New York Lung Cancers Symposium, the advances that have been made over the past year, and potential routes forward in advancing the field of lung cancer.

Chemoimmunotherapy Transforms the Lung Cancer Armamentarium

December 2nd 2020

Vignesh Narayanan, MD, the role of chemoimmunotherapy and how it has truly changed the game in the treatment of patients with lung cancer.

FDA Grants Fast Track Status to Irinotecan Liposome Injection for Second-Line SCLC

December 1st 2020

December 1, 2020 — The FDA has granted a fast track designation to irinotecan liposome injection as second-line monotherapy option for patients with small cell lung cancer whose disease progressed following a platinum-based chemotherapy regimen.

EMA Accepts Application for Tepotinib for METex14+ NSCLC

November 30th 2020

November 30, 2020 - The European Medicines Agency has validated an application to review tepotinib for the treatment of adult patients with advanced non–small cell lung cancer that harbor MET exon 14 skipping alterations.

Immunotherapy Leads the Way in Lung Cancer, but Creates Complex Treatment Decisions

November 27th 2020

Joshua Reuss, MD, discusses the lung cancer armamentarium, the role of immunotherapy combinations, and the significance of biomarkers.

PD-L1 Status Stratifies Immunotherapy Treatment in NSCLC

November 25th 2020

Data from completed studies evaluating immunotherapy in lung cancer alone or in combination with chemotherapy show that a breakdown of populations by PD-L1 status and additional considerations such as toxicity profiles should guide treatment decisions.

TILs, the Ultimate in Personalized Immunotherapy, Move Closer to Market

November 24th 2020

November 24, 2020 - Until now, the field of cell-based immunotherapy has been dominated by chimeric antigen receptor (CAR) T cells, with groundbreaking FDA approvals for 3 drugs across several types of hematologic malignancies. In solid tumors, however, CAR T-cell therapies have yet to gain ground.

Dr. Chaft on the Rationale for the OPAL Trial in EGFR+ NSCLC

November 23rd 2020

Jamie E. Chaft, MD, discusses the rationale behind the ​OPAL trial in EGFR-mutant non–small cell lung cancer.

Oxnard on Opening the Door for Precision Medicine in Lung Cancer

November 23rd 2020

In our exclusive interview, Dr. Oxnard explained how precision medicine has affected the treatment landscape of lung cancer, discussed the current capabilities of liquid biopsy, and forecasted the future of precision oncology in the field.

Sugemalimab/Chemo Combo Elicits Clinically Meaningful PFS Benefit in Metastatic NSCLC

November 21st 2020

November 21, 2020 - The addition of sugemalimab to chemotherapy demonstrated a statistically significant and clinically meaningful progression-free survival benefit in the frontline treatment of patients with metastatic non–small cell lung cancer versus placebo plus chemotherapy.